4ATB
| |
4AT9
| |
4AT7
| Crystal structure of the NF90-NF45 dimerisation domain complex | Descriptor: | DI(HYDROXYETHYL)ETHER, INTERLEUKIN ENHANCER-BINDING FACTOR 2, INTERLEUKIN ENHANCER-BINDING FACTOR 3, ... | Authors: | Wolkowicz, U.M, Cook, A.G. | Deposit date: | 2012-05-05 | Release date: | 2012-08-01 | Last modified: | 2024-05-01 | Method: | X-RAY DIFFRACTION (1.902 Å) | Cite: | NF45 Dimerizes with NF90, Zfr and Spnr Via a Conserved Domain that Has a Nucleotidyltransferase Fold. Nucleic Acids Res., 40, 2012
|
|
4AT8
| |
4MDB
| Structure of Mos1 transposase catalytic domain and Raltegravir with Mg | Descriptor: | MAGNESIUM ION, Mariner Mos1 transposase, N-(4-fluorobenzyl)-5-hydroxy-1-methyl-2-(1-methyl-1-{[(5-methyl-1,3,4-oxadiazol-2-yl)carbonyl]amino}ethyl)-6-oxo-1,6-di hydropyrimidine-4-carboxamide | Authors: | Richardson, J.M. | Deposit date: | 2013-08-22 | Release date: | 2014-01-22 | Last modified: | 2023-09-20 | Method: | X-RAY DIFFRACTION (1.7 Å) | Cite: | Structural Basis of Mos1 Transposase Inhibition by the Anti-retroviral Drug Raltegravir. Acs Chem.Biol., 9, 2014
|
|
4MDA
| Structure of Mos1 transposase catalytic domain and Raltegravir with Mn | Descriptor: | MANGANESE (II) ION, Mariner Mos1 transposase, N-(4-fluorobenzyl)-5-hydroxy-1-methyl-2-(1-methyl-1-{[(5-methyl-1,3,4-oxadiazol-2-yl)carbonyl]amino}ethyl)-6-oxo-1,6-di hydropyrimidine-4-carboxamide | Authors: | Richardson, J.M. | Deposit date: | 2013-08-22 | Release date: | 2014-01-22 | Last modified: | 2023-09-20 | Method: | X-RAY DIFFRACTION (1.7 Å) | Cite: | Structural Basis of Mos1 Transposase Inhibition by the Anti-retroviral Drug Raltegravir. Acs Chem.Biol., 9, 2014
|
|